CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor

Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells

(2019) Cornelia Kröger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD44 splice isoform switching determines breast cancer stem cell state

(2019) Honghong Zhang et al.   GENES & DEVELOPMENT

Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes

(2019) Nazanin Rohani et al.   CANCER RESEARCH

Ezrin promotes breast cancer progression by modulating AKT signals

(2019) Nan Li et al.   BRITISH JOURNAL OF CANCER

Inducible formation of leader cells driven by CD44 switching gives rise to collective invasion and metastases in luminal breast carcinomas

(2019) Cuixia Yang et al.   ONCOGENE

The role of alternative splicing in cancer drug resistance

(2018) Zahava Siegfried et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

The biology and role of CD44 in cancer progression: therapeutic implications

(2018) Chen Chen et al.   Journal of Hematology & Oncology

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

(2018) André Kahles et al.   CANCER CELL

Extracellular matrix protein 1 recruits moesin to facilitate invadopodia formation and breast cancer metastasis

(2018) Qiuwan Wu et al.   CANCER LETTERS

Nuclear Shp2 directs normal embryo implantation via facilitating the ERα tyrosine phosphorylation by the Src kinase

(2017) Hao Ran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A

(2017) Wei Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D

(2017) Eneda Toska et al.   SCIENCE

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition

(2016) Pau Castel et al.   CANCER CELL

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer

(2016) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy

(2016) Shujie Zhao et al.   CLINICAL CANCER RESEARCH

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

(2016) X. Le et al.   Cancer Discovery

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

(2015) Moshe Elkabets et al.   CANCER CELL

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

(2015) Carlotta Costa et al.   CANCER CELL

Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ

(2015) Sarit Schwartz et al.   CANCER CELL

Empirical inference of circuitry and plasticity in a kinase signaling network

(2015) Edmund H. Wilkes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

(2015) Ana Bosch et al.   Science Translational Medicine

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

(2014) Sadhna R. Vora et al.   CANCER CELL

Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

(2014) Nicola Aceto et al.   CELL

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

(2014) Dejan Juric et al.   NATURE

Alternative splicing in cancer: implications for biology and therapy

(2014) J Chen et al.   ONCOGENE

Lipid Raft Association Restricts CD44-Ezrin Interaction and Promotion of Breast Cancer Cell Migration

(2012) Simona Donatello et al.   AMERICAN JOURNAL OF PATHOLOGY

p53, a Target of Estrogen Receptor (ER) α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells

(2012) Crystal E. Berger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Estrogen receptor prevents p53-dependent apoptosis in breast cancer

(2012) S. T. Bailey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer

(2011) Muralidharan Anbalagan et al.   BREAST CANCER RESEARCH AND TREATMENT

Hyaluronan Synthase HAS2 Promotes Tumor Progression in Bone by Stimulating the Interaction of Breast Cancer Stem-Like Cells with Macrophages and Stromal Cells

(2011) H. Okuda et al.   CANCER RESEARCH

Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells

(2011) Piyush B. Gupta et al.   CELL

CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression

(2011) Rhonda L. Brown et al.   JOURNAL OF CLINICAL INVESTIGATION

Hyaluronan-CD44 Interaction Promotes c-Src-mediated Twist Signaling, MicroRNA-10b Expression, and RhoA/RhoC Up-regulation, Leading to Rho-kinase-associated Cytoskeleton Activation and Breast Tumor Cell Invasion

(2010) Lilly Y. W. Bourguignon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression

(2008) Samuel Godar et al.   CELL